# Lilly Statement on Mounjaro® (tirzepatide) U.S. International Trade Commission Complaint

October 19, 2023

Lilly has filed a complaint before the U.S. International Trade Commission to stop companies from importing, selling, or distributing what those companies assert is tirzepatide, the active pharmaceutical ingredient (API) in Mounjaro®. The FDA does not review the products these companies are importing or distributing for safety, quality, or efficacy — nor does any other global regulatory agency. In fact, testing shows that at least one of the companies purporting to sell tirzepatide was actually selling nothing more than sugar alcohol. Lilly is committed to patient safety and, therefore, seeks to prevent these companies from exposing patients to potentially serious health risks.

###